Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087512 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kyung-Hee Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Chungnam National University School of Medicine, Munwha-ro 282, Daejeon 35015, Republic of Korea. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Cell-Free Nucleic Acids, Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health & Welfare, Republic of Korea, Korean government (MSIT), Chungnam National University Sejong Hospital Research Fund, 2022.
Abstract (Originalsprache)
Cholangiocarcinoma is a malignant epithelial tumor arising from bile ducts that is frequently fatal. Diagnosis is difficult due to tumor location in the biliary tract. Earlier diagnosis requires less invasive methods of identifying effective biomarkers for cholangiocarcinoma. The present study investigated the genomic profiles of cell-free DNA (cfDNA) and DNA from corresponding primary cholangiocarcinomas using a targeted sequencing panel. Somatic mutations in primary tumor DNA and circulating tumor DNA (ctDNA) were compared and clinical applications of ctDNA validated in patients with cholangiocarcinoma. A comparison of primary tumor DNA and ctDNA identified somatic mutations in patients with early cholangiocarcinomas that showed clinical feasibility for early screening. The predictive value of single-nucleotide variants (SNVs) of preoperative plasma cfDNA positive for somatic mutations of the primary tumor was 42%. The sensitivity and specificity of postoperative plasma SNVs in detecting clinical recurrence were 44% and 45%, respectively. Targetable fibroblast growth factor receptor 2 (FGFR2) and Kirsten rat sarcoma virus (KRAS) mutations were detected in 5% of ctDNA samples from patients with cholangiocarcinoma. These findings showed that genomic profiling of cfDNA was useful in clinical evaluation, although ctDNA had limited ability to detect mutations in cholangiocarcinoma patients. Serial monitoring of ctDNA is important clinically and in assessing real-time molecular aberrations in cholangiocarcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Chungnam National University School of Medicine, Munwha-ro 282, Daejeon 35015, Republic of Korea.
- Laboratory of Endocrinology and Immune System, Chungnam National University School of Medicine, Daejeon 35015, Republic of Korea.
ORCID-Profile: Kyung-Hee Kim, Min-Kyung Yeo
Förderung
- Ministry of Health & Welfare, Republic of Korea
- Korean government (MSIT)
- Chungnam National University Sejong Hospital Research Fund, 2022
- Ministry of Health & Welfare, Republic of Korea
- Chungnam National University Sejong Hospital Research Fund
Zitieren
APA
Kim, K. H., Yi, H. S., Lee, H., Bae, G. E., & Yeo, M. K. (2023). Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087512
Vancouver
Kim KH, Yi HS, Lee H, Bae GE, Yeo MK. Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087512
BibTeX
@article{Kim2023,
author = {Kim, Kyung-Hee and Yi, Hyon-Seung and Lee, Hyunjung and Bae, Go-Eun and Yeo, Min-Kyung},
title = {Targeting the Sequences of Circulating Tumor DNA of Cholangiocarcinomas and Its Applications and Limitations in Clinical Practice},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087512}
}
EUVIMED